Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

ERC grant for Stefan Pfister: “We must further advance pediatric cancer research”

No. 04 | 28/01/2019 | by Mat

KiTZ director Stefan Pfister, professor of pediatric neurooncology at the German Cancer Research Center (DKFZ) and the Heidelberg University Hospital, succeeded in gaining one of the prestigious ERC Consolidator Grants for his project entitled "BRAIN-MATCH". The goal of BRAIN-MATCH is to characterize normal brain development using molecular-biological methods and to compare it with the development of brain cancer. Pfister and his team plan to use the results obtained as a basis for finding new approaches in the treatment of brain cancer in children. The European Research Council (ERC) awards "Consolidator Grants" to support excellent scientists who are expanding their research activities.
The "Hopp Children's Cancer Center Heidelberg" (KiTZ) is a joint institution of the German Cancer Research Center (DKFZ), Heidelberg University Hospital (UKHD) and Heidelberg University.

KiTZ director Stefan Pfister has received an ERC Consolidator Grant.
© KiTZ

"I am very pleased about the ERC Consolidator Grant, which is a high distinction for our research," said Pfister. "We will use the funds to expand our activities in investigating normal brain development and identifying parallels with the development of pediatric brain tumors. We will use the findings we obtain for the systematic search for new therapy approaches."

Although childhood cancer is generally considered to be well treatable, there are still some subtypes of cancer of the central nervous system that fail to respond or respond with difficulty to therapy – despite all medical progress made over the past decades.

Pfister and his team will use the ERC grant to study more than 30,000 tissue samples from over 100 different types of brain tumor using the most advanced analysis and IT methods. In this study, the scientists will take account of molecular differences between tumor types and also of various stages of carcinogenesis. In order to better comprehend the biological causes of tumor development, the researchers plan to make comprehensive comparisons between healthy brain tissue and tumor tissue. From the differences found they will draw conclusions about the causes of tumor development in order to find clues towards new treatment approaches.

Childhood cancer types are often fundamentally different from adult cancer types which may look similar or the same under the microscope. Findings from cancer research concerning adults can therefore not be transferred unmodified to pediatric oncology. "It is crucial that we further advance pediatric cancer research in order to gain a better understanding of the biology of pediatric tumor types," Pfister explained. "Our goal is to be also able to help those approximately 20 percent of children with cancer for whom there is no suitable treatment method so far." He added: "The support of our project BRAIN-MATCH by the ERC is an important contribution towards this goal." The project is scheduled for a period of five years and will receive ERC Grant funds of € 2 million.

In 2018, the European Research Council awarded 291 Consolidator Grants with a total budget volume of € 573 million, as part of the Horizon 2020 project. Twenty-five of the grants went to German scientists.

An image for this press release is available for download at: 

KiTZ director Stefan Pfister has received an ERC Consolidator Grant.

Note on use of images related to press releases
Use is free of charge. The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) permits one-time use in the context of reporting about the topic covered in the press release. Images have to be cited as follows: "Source: KiTZ".
Distribution of images to third parties is not permitted unless prior consent has been obtained from DKFZ's Press Office (phone: ++49-(0)6221 42 2854, E-mail: Any commercial use is prohibited.

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS